Clinical Trial Update: Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating bortezomib plus dexamethasone for relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Sparrow Regional Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: UNKNOWN